NCT03768596 is a NA clinical trial of Nudge in Influenza, Human, sponsored by Adriaan Barbaroux.

Who is sponsoring NCT03768596?

NCT03768596 is sponsored by Adriaan Barbaroux.

What drugs are being tested in NCT03768596?

Interventions in NCT03768596: Nudge, vaccination form.

What condition does NCT03768596 study?

NCT03768596 studies Influenza, Human, Vaccination; Sepsis.

Is NCT03768596 still recruiting?

NCT03768596 is currently completed. Last updated 10 January 2019.

Last reviewed 2019-01-10 · How we verify

NCT03768596

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nudging for Vaccination : Efficacity and Acceptability Among Medical Students

Completed NA Last updated 10 January 2019

What this trial tests

NA trial testing Nudge in Influenza, Human in 200 participants. Completed in 20 December 2018.

Timeline

7 November 2018

Primary endpoint
20 December 2018

20 December 2018

Quick facts

Lead sponsor	Adriaan Barbaroux
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	200
Start date	7 November 2018
Primary completion	20 December 2018
Estimated completion	20 December 2018
Sites	1 location across France

Drugs / interventions tested

Nudge
vaccination form

Conditions studied

Influenza, Human — all drugs for Influenza, Human →
Vaccination; Sepsis — all drugs for Vaccination; Sepsis →

Sponsor

Adriaan Barbaroux

Who can join

Eligibility, any sex, with Influenza, Human or Vaccination; Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nudge is a set of methods aimed at helping people adopt a behavior by a gentle prompt, conscious or not. Classically, Nudges rely on heuristics and cognitive biases. These methods have been studied for years in social psychology and are receiving renewed attention since the awarding of the Nobel Prize in economics to Richard Thaler for his work on the application of Nudge to the economy. Health professionals are very inadequately vaccinated (25 to 45% of the population). Some studies have shown that a Nudge based on intent implementation can significantly increase vaccination coverage. However, few studies evaluate the acceptability of Nudge or its application to health professionals. The investigators sought to apply a Nudge based on availability heuristics to health professionals, in order to evaluate its effectiveness and terms of behavior adoption (influenza vaccination) and its acceptability. The investigator's hypothesis is that Nudging is both effective and acceptable and that people found nudging more acceptable if they have been exposed to a nudge.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nudging health care workers towards a flu shot: reminders are accepted but not necessarily effective. A randomized controlled study among residents in general practice in France.
Barbaroux A, Benoit L, Raymondie RA, Milhabet I. · · 2021 · cited 6× · PMID 33506858 · DOI 10.1093/fampra/cmab001

Verify or expand the search:

Other trials of Nudge

Trials testing the same drug.

NCT07078409 — Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology · NA · enrolling by invitation
NCT06451263 — Nudge to Gynecologic Oncology · NA · active not recruiting
NCT05613751 — Enhancing Protection Against Influenza and COVID-19 for Pregnant Women and Medically at Risk Children · NA · unknown
NCT05250778 — Nudges on Hospitalist Behavior and Patient Satisfaction · NA · completed
NCT04844021 — Adolescent and Child Suicide Prevention in Routine Clinical Encounters · NA · completed

Other recruiting trials for Influenza, Human

Currently open trials in the same condition.

NCT07204964 — A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above · Phase 2 · active not recruiting
NCT07121192 — A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older · Phase 2 · active not recruiting
NCT05921448 — Vaccine Pandemic Preparedness Through Airway Immunology Characterization · EARLY_PHASE1 · active not recruiting
NCT06573008 — Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications · Phase 3 · recruiting
NCT06622590 — Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03768596 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adriaan Barbaroux
Last refreshed: 10 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03768596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing